Saturday, September 25, 2021

Tax Notes: Updated comprehensive list of FDA-approved VAT-exempt products under the Create Act

Pursuant to the provisions on Value-Added Tax (VAT) exemptions under the Corporate Recovery and Tax Incentives for Enterprises (Create) Act, the Bureau of Internal Revenue (BIR) issued Revenue Memorandum Circular (RMC) 81-2021 to inform the public regarding the updated and consolidated list of VAT-exempt products, including the following:

a. Medicines for diabetes, high cholesterol and hypertension beginning Jan. 1, 2020

b. Medicines for cancer, mental illness, tuberculosis and kidney diseases beginning Jan. 1, 2021;

c. Drugs and vaccines prescribed and directly used for coronavirus disease (Covid-19) treatment beginning Jan. 1, 2021 until Dec. 31. 2023; and,

d. Medical devices directly used for Covid-19 treatment beginning Jan. 1, 2021 until Dec. 31, 2023.

RMC 81-2021 amends the previously circularized lists through RMC 4-2019, 62-2020 and 101-2020, following the implementation of Republic Act No. 10963, otherwise known as the Tax Reform for Acceleration and Inclusion Law.

The complete list of VAT-exempt products can be accessed in the following websites:

a. Bureau of Internal Revenue (;

b. Department of Health (; and,

c. Food and Drug Administration (

Please be guided accordingly.

Source: P&A Grant Thornton


SunStar website welcomes friendly debate, but comments posted on this site do not necessarily reflect the views of the SunStar management and its affiliates. SunStar reserves the right to delete, reproduce or modify comments posted here without notice. Posts that are inappropriate will automatically be deleted.

Forum rules:

Do not use obscenity. Some words have been banned. Stick to the topic. Do not veer away from the discussion. Be coherent. Do not shout or use CAPITAL LETTERS!

Create your own user feedback survey